Jul 20, 2024, 21:00
Nelson Dusetti: We are grateful to INCa for funding our project – NeoPREDICT
“We are grateful to INCa for funding our project NeoPREDICT: A multicentric phase II trial to personalize neoadjuvant chemotherapy for patients with borderline resectable pancreatic adenocarcinoma using the Pancreas View signature.”
Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43
Nov 12, 2024, 19:34